Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04337684

Long Term Follow-up on Menkes Disease Patients

Sponsor: Sentynl Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study will collect long term follow-up data regarding overall survival and neurological parameters from patients previously identified and/or enrolled in Protocols 09-CH-0059 and 90-CH0149 and Historical Control data on Menkes disease patients.

Official title: Long Term Follow-Up and Collection of Historical Control Data on Menkes Disease Patients

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

50

Start Date

2019-12-01

Completion Date

2026-08-31

Last Updated

2026-03-02

Healthy Volunteers

Not specified

Conditions

Interventions

DRUG

Long Term Follow-Up

Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data. During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up.

Locations (1)

Sentynl Therapeutics

Solana Beach, California, United States